News Search Results
Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity
chronic lymphocytic leukemia (CLL)". In the lung cancer study, early on-treatment weight gain was a favorable survival association, with each 1% increase in body weight after pembrolizumab initiation consistently associated with lower subsequent mortality risk. In the CLL study of 3,542 patients initiating
More news about: nference
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
oral and poster presentations:Predicted efficacy of venetoclax-based therapies in CLL based on genetic biomarkersResults from the Phase 3 GAIA/CLL13 (
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
oral and poster presentations:Predicted efficacy of venetoclax-based therapies in CLL based on genetic biomarkersResults from the Phase 3 GAIA/CLL13 (
More news about: AbbVie
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
head-to-head clinical trial comparing rocbrutinib with the third-generation non-covalent BTK inhibitor pirtobrutinib for the treatment of R/R CLL/SLL (the ROCKET-CLL study, NCT07342478) was launched, marking a new stage in rocbrutinib's global development.
More news about: Lupeng Pharmaceutical Ltd
Jun 02, 2026, 09:30 ET Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
BRUIN CLL-322 study, evaluating a time-limited regimen of pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL. BRUIN CLL-322 is the first Phase 3 readout in CLL to outperform a venetoclax-containing control arm in any CLL setting.
More news about: Eli Lilly and Company
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
leukemia (CLL). The expanded label follows the EC's inclusion of these combinations in the acalabrutinib and ibrutinib labels. These all-oral, fixed-duration combination regimens support current standards of care and offer patients and providers additional targeted oral medications for CLL in the first-line
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
leukemia (CLL). The expanded label follows the EC's inclusion of these combinations in the acalabrutinib and ibrutinib labels. These all-oral, fixed-duration combination regimens support current standards of care and offer patients and providers additional targeted oral medications for CLL in the first-line
More news about: AbbVie
May 28, 2026, 12:30 ET Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
high-value B-cell, T-cell, and lymphoblastic markers including full coverage of BTK to help genomically characterize lymphoid malignancies including CLL/SLL, WM/LPL, FL, MCL, DLBCL/LBCL, HCL, and multiple T-cell entities.These oncoReveal panels are currently available to customers worldwide.Expanding
More news about: Illumina, Inc.
May 21, 2026, 22:40 ET 【2026 ASCO】亞盛醫藥公佈多項臨床進展，三項獲快速口頭報告
randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress利沙托克拉（APG-2575）治療既往經治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者的全球多中心、開放性、隨機
More news about: 亞盛醫藥
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Pirtobrutinib in treatment-naïve patientswith CLL/SLL: Pooled results from BRUINCLL-313 and BRUIN CLL-314William G.Wierda
More news about: Eli Lilly and Company
May 21, 2026, 10:00 ET Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
(R/R CLL/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi). Existing BTK inhibitors face resistance challenges, underscoring the need for next-generation therapies that can overcome resistance.The first study site of the ROCKET-CLL Phase 3 trial (LP-168-US-CLL301;
More news about: Lupeng Pharmaceutical Ltd
May 12, 2026, 22:33 ET 【EHA2026】亞盛醫藥17項臨床進展入選2026年歐洲血液學協會年會
01:45（北京時間）第一作者：陳蘇寧教授，蘇州大學附屬第一醫院CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY一項關鍵II期臨床研究中利沙托克拉（APG-2575）治療的慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者基線特徵與預後的相關性
More news about: 亞盛醫藥
May 12, 2026, 16:00 ET Curis Provides First Quarter 2026 Business Update
PCNSL.TakeAim CLL Emavusertib is also being tested in the recently initiated open label TakeAim CLL Phase 2 clinical trial of emavusertib in combination with the BTKi zanubrutinib in patients with Chronic Lymphocytic Leukemia (CLL) (CA-4948-203, NCT07271667).
More news about: Curis, Inc.
May 12, 2026, 14:19 ET Binaytara's 2026 National Summit on Hematologic Cancers Reinvents the Medical Conference -- and Invests $250,000 Behind the Next Generation of Researchers
the "Gray Zone" format: case-based sessions in which two to three real-world hematology cases — in leukemia, lymphoma, multiple myeloma, MPN/CML, and CLL — unfold in clinical layers, with expert panelists engaging in open, unscripted deliberation. Moderators are explicitly instructed to surface conflict,
More news about: Binaytara
May 06, 2026, 10:00 ET Dee and Jimmy Haslam Make $12.5 Million Transformational Investment in Blood Cancer Research and Treatments at University Hospitals
focused on CLL and related blood cancers via the Oxford-Harrington Rare Disease Centre, which is dedicated to creating breakthrough medicines for rare conditions with limited or no existing therapies. An additional $2.5 million will benefit UH Seidman Cancer Center, establishing an endowed chair in CLL research
More news about: Harrington Discovery Institute
May 06, 2026, 10:00 ET Dee and Jimmy Haslam Make $12.5 Million Transformational Investment in Blood Cancer Research and Treatments at University Hospitals
focused on CLL and related blood cancers via the Oxford-Harrington Rare Disease Centre, which is dedicated to creating breakthrough medicines for rare conditions with limited or no existing therapies. An additional $2.5 million will benefit UH Seidman Cancer Center, establishing an endowed chair in CLL research
More news about: Harrington Discovery Institute
May 05, 2026, 17:11 ET Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML)
More news about: Curis, Inc.
Apr 30, 2026, 06:45 ET Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
diabetes and obesity or overweight at increased cardiovascular risk, Jaypirca in combination with venetoclax and rituximab in relapsed or refractory CLL or SLL, Taltz and Zepbound used together for adults with psoriasis and obesity or overweight, and retatrutide in type 2 diabetes.Business
More news about: Eli Lilly and Company
Apr 29, 2026, 07:47 ET AbbVie Reports First-Quarter 2026 Financial Results
treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). This approval establishes the Venclexta and acalabrutinib combination as the first all-oral, fixed-duration regimen for previously untreated CLL, offering patients the potential of time off treatment. The approval is supported
More news about: AbbVie
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
ongoing recruitment; Additionally, new preclinical data supporting opaganib potential as add-on therapy in Chronic Lymphocytic Leukemia (CLL)2, neuroblastoma3 and Triple Negative Breast Cancer4 therapy was reported Discussions
More news about: RedHill Biopharma Ltd.
Apr 26, 2026, 21:50 ET 亞盛醫藥Bcl-2抑制劑利生妥®獲 2026 版 CSCO系列指南多項重磅推薦
一、 CLL/SLL 領域：實現從單藥到聯合的全覆蓋在2026版《CSCO 淋巴瘤診療指南》中，利沙托克拉形成了階梯式的精準化佈局：I 級推薦（單藥/復發難治）：基於APG2575CC201研究在高危、BTKi經治人群中的顯著獲益（ORR達62.5%），利沙托克拉單藥獲I級推薦（高證據級別），成為復發難治性CLL/SLL患者的標準治療方案
More news about: 亞盛醫藥
Apr 21, 2026, 21:26 ET 【2026 ASCO】亞盛醫藥多項研究入選，其中三項獲快速口頭報告
randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress利沙托克拉（APG-2575）治療既往經治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者的全球多中心、開放性、隨機
More news about: 亞盛醫藥
Apr 13, 2026, 06:45 ET Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
clinicaltrials.gov.About BRUIN CLL-322BRUIN CLL-322 is a global, randomized, open-label, Phase 3 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated CLL/SLL patients. The trial enrolled 639 patients,
More news about: Eli Lilly and Company
Mar 19, 2026, 16:00 ET Curis Provides Fourth Quarter 2025 Business Update
both FDA and EMA in PCNSL.TakeAim CLL Curis initiated an open label Phase 2 clinical study of emavusertib in combination with zanubrutinib, a BTKi, in patients with Chronic Lymphocytic Leukemia (CLL). The goal of combining emavusertib with a BTKi is to
More news about: Curis, Inc.
Mar 12, 2026, 16:27 ET Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company has completed its monotherapy and combination studies in acute myeloid
More news about: Curis, Inc.